Risk of a second kidney carcinoma following childhood cancer:role of chemotherapy and radiation dose to kidneys by De Vathaire, Florent et al.
 
 
University of Birmingham
Risk of a second kidney carcinoma following
childhood cancer
De Vathaire, Florent; Scwhartz, Boris; El-fayech, Chiraz; Allodji, Rodrigue Sètchéou;
Escudier, Bernard; Hawkins, Michael; Diallo, Ibrahima; Haddy, Nadia
DOI:
10.1016/j.juro.2015.06.092
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
De Vathaire, F, Scwhartz, B, El-fayech, C, Allodji, RS, Escudier, B, Hawkins, M, Diallo, I & Haddy, N 2015, 'Risk
of a second kidney carcinoma following childhood cancer: role of chemotherapy and radiation dose to kidneys',
Journal of Urology. https://doi.org/10.1016/j.juro.2015.06.092
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository: Checked on 14/09/2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Author's Accepted Manuscript
Risk of a Second Kidney Carcinoma Following Childhood Cancer: Role of
Chemotherapy and of Radiation Dose to Kidneys
Florent de Vathaire , Boris Scwhartz , Chiraz El-Fayech , Rodrigue Sètchéou
Allodji , Bernard Escudier , Mike Hawkins , Ibrahima Diallo , Nadia Haddy
PII: S0022-5347(15)04306-2
DOI: 10.1016/j.juro.2015.06.092
Reference: JURO 12732
To appear in: The Journal of Urology
Accepted Date: 2 June 2015
Please cite this article as: de Vathaire F, Scwhartz B, El-Fayech C, Allodji RS, Escudier B, Hawkins
M, Diallo I, Haddy N, Risk of a Second Kidney Carcinoma Following Childhood Cancer: Role of
Chemotherapy and of Radiation Dose to Kidneys, The Journal of Urology® (2015), doi: 10.1016/
j.juro.2015.06.092.
DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a
service to our subscribers we are providing this early version of the article. The paper will be copy edited
and typeset, and proof will be reviewed before it is published in its final form. Please note that during the
production process errors may be discovered which could affect the content, and all legal disclaimers
that apply to The Journal pertain.
Embargo Policy
All article content is under embargo until uncorrected proof of the article becomes available
online.
We will provide journalists and editors with full-text copies of the articles in question prior to the embargo
date so that stories can be adequately researched and written. The standard embargo time is
12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
RISK OF A SECOND KIDNEY CARCINOMA FOLLOWING CHILDHOOD CANCER: ROLE OF 
CHEMOTHERAPY AND OF RADIATION DOSE TO KIDNEYS 
 
Florent de Vathaire a,b,c,Boris Scwhartz a,b,c, Chiraz El-Fayecha,b,c, Rodrigue Sètchéou 
Allodjia,b,c, Bernard Escudierb, Mike Hawkinsd, , Ibrahima Dialloa,b,c, Nadia Haddya,b,c. 
a Radiation Epidemiology Group, INSERM U1018 94805 Villejuif, France  
b Institut Gustave Roussy, 94805 Villejuif, France  
c Univ. Paris-Sud, 94800 Villejuif, France 
 
d Centre for Childhood Cancer Survivor Studies, Department of Public Health & 
Epidemiology, University of Birmingham, UK 
Running title: 
KIDNEY CARCINOMA AFTER CHEMOTHERAPY AND RADIOTHERAPY 
Corresponding author  
Florent de Vathaire.  
Radiation Epidemiology Group.  
Unit 1018-Team 3; INSERM,  
Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France. 
 Tel +33.1.42.11.54.57.   
Fax +33.1.42.11.56.18.   
E-mail: florent.devathaire@gustaveroussy.fr 
Conflict of interest: 
We declare no conflicts of interest. 
Key words:  
Childhood cancer, radiotherapy, chemotherapy, kidney carcinoma (KC), radiation doses. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
ABSTRACT 
BACKGROUND: Kidney carcinoma (KC) is a rare second malignant carcinoma following 
childhood cancer.  
METHODS: In order to quantify the risk of KC following childhood cancer treatment, and to 
assess its risk factors, we followed over 27 years on average, a cohort of 4,350 5-year 
childhood cancer survivors treated between 1943 and 1985, in France and UK. Radiation 
dose received to the two kidneys during radiotherapy was estimated with dedicated 
software whatever the site of the childhood cancer. 
RESULTS: Thirteen patients had developed a KC. The cumulative incidence of KC was 
0.62% (95%CI: 0.27% - 1.45%), 40 years after diagnosis, i.e. 13.3-fold higher (95%CI: 7.1-
22.3) than that expected in the general population. The absolute excess risk strongly 
increased (p<0.0001) with longer duration of follow-up. Compared to the general 
population, the incidence of KC was 5.7-fold higher (95%CI: 1.4-14.7) if no radiation 
therapy or less than 1 Gy had been absorbed by the kidney, but 66.3-fold higher (95%CI: 
23.8-142.5) if the radiation dose to the kidneys was between 10 and 19 Gy, and 14.5-fold 
greater (95%CI: 0.8-63.9) for higher radiation doses to the kidney. Treatment with 
chemotherapy increased the risk of KC (RR=5.1, 95%CI: 1.1-22.7), but we were not able to 
identify a specific drug or drug category responsive for this increase. 
CONCLUSIONS: Moderate radiation dose to the kidneys during childhood cancer treatment 
increased the risk of a second KC whose incidence will be on the increase when childhood 
cancer survivors reach old ages. 
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INTRODUCTION 
Survival after childhood cancer has strongly increased since the 1970s with 5-year survival 
rates now approaching 80%. Second primary cancers are among the most serious late 
effects of chemotherapy and radiation therapy and are an increasing concern regarding 
childhood cancer survivors [1,2,3,4]. 
Although genito-urinary cancers as a whole have been addressed in some large cohort 
studies [1,2,3,4], to date very few studies have investigated kidney carcinoma (KC) as a 
specific issue after childhood cancer [5,6,7]. The main explanation is that KC as a second 
malignancy following childhood cancer is still very rare, because most of the childhood 
cancer survivors are still quite young, below 50 years, age at which KC is very rare in the 
general population. [8].  
Recently a publication of the large Childhood Cancer Survivor Study (CCSS) [5] concluded 
that a radiation dose to kidney of 5 Gy or higher increases the risk of KC by 3.8 (95%CI: 1.6-
9.3), and that administration of platinum based chemotherapy increased this risk by 3.5 
(95%CI: 1.0-11.2). Because this is, at this time, the only study focused on KC as a second 
malignancy following childhood cancer, these results had to be confirmed. 
We studied the role of the first cancer type, type of treatment, and radiation dose 
absorbed by the kidney during radiation therapy on the risk of a second KC following 
childhood cancer treatment. 
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MATERIAL AND METHODS 
PATIENTS 
A retrospective cohort of children treated in 8 centers in France and the UK was 
constituted from 1985 to 1995, comprising patients who were alive 2 (France) or 3 (UK) 
years after a first solid cancer that was diagnosed before 16 years of age and before 1986. 
The method of constitution of the cohort has been firstly described in 1995 [9]. In this first 
publication, the cohort included 4,567 patients. From 1995 to 2009, some French patients 
have been excluded because of diagnostic errors and duplicate entries, and some others 
have been added, who were initially missed because some medical records were not 
available at time of initial cohort constitution, but were discovered during a systematic 
investigation in Gustave Roussy Institute archives performed afterward. The final database 
includes 4,649 patients, of whom 4,389 were five -year survivors.  
Of these 4,389 patients, 39 patients who had undergone a bilateral nephrectomy (n=39) 
were excluded from the analysis. The 4,350 (3,133 treated in France) remaining patients 
were included in the present study (Table 1). 
The follow-up of the 3,133 French patients was initially assessed using the medical records 
from treatment centers, and later via a self-completed questionnaire sent from September 
2005. This questionnaire based on that of the Childhood Cancer Survivor Study (CCSS) [10], 
provided information on the health outcomes. A total of 2,455 patients were still alive and 
therefore considered eligible for the questionnaire. This was sent by regular mail to the 
2,105 patients for whom the most recent address was obtained and who had returned a 
signed consent agreement. A total of 1,920 (74% of 2,455) patients returned the completed 
questionnaire by December 31, 2012. 
The 1,217 UK patients were monitored for the occurrence of KC and death using the 
National Health Service Central Registers [11,12].  
RADIATION DOSIMETRY 
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The radiation dose was estimated in the center for each of the two kidneys for each 
patient who had received radiation therapy. The doses to most of the other anatomical 
sites including the spleen, and gonads were also estimated. The Dos_EG software was 
developed for these calculations [13,14]. The mean dose of radiation absorbed by the 
kidney was 8.6 Gy, the median value being 1.5 Gy (range: 0 to 66.2) (Figure 1). 
CHEMOTHERAPY  
Drugs were pooled into 6 classes according to their known mechanisms of action within 
the cell: Anthracyclines, alkylating agents, epipodophyllotoxins, antimetabolites, Vinca 
alkaloids and other drugs. The cumulative dose of each cytotoxic drug was recorded. For 
alkylating agents, we o compute the cyclophosphamide dose equivalent score for toxicity 
proposed by Green et al [15]. 
STATISTICAL METHODS  
We used estimates of the French national cancer incidence rates as reference rates for 
patients treated in French centers [16] and the UK-national cancer incidence rates for 
those treated in the UK [11]. The standardized incidence ratio (SIR), calculated as the ratio 
of the observed number of KCs to the expected number, was assessed statistically by 
considering that the observed number follows a Poisson distribution [16]. The absolute 
excess risk (AER) was calculated as the difference between the observed and expected 
number of KCs divided by the number of person-years of follow-up.  
As the two kidneys of a given child may have received very different radiation doses 
during radiation therapy, we performed analyses of the relationship between the radiation 
dose absorbed by the kidney and the risk of KC using the kidney as the statistical unit. So, 
in these analyses, each patient counts for two kidneys, except the 877 patients who had a 
unilateral nephrectomy who only count for their remaining kidney. 
An internal analysis was conducted using clustered Cox’s proportional hazard regression 
model for aggregated data, in order to take into account the lack of independence 
between the two kidneys of the same subject [17].  
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In order to evaluate the dose-effect relationship between the kidney radiation dose and 
the risk of KC, we tested linear (1) and linear exponential (2) models by comparing nested 
models [18].  
1. Linear =  Relative Risk = Cst. [1 + α dose] 
2. Linear exponential Relative Risk = Cst. [1 + α  dose × exp(β dose)] 
Cst = constant; α,β = coefficients ; dose = kidney radiation dose  
The DATAB and AMFIT modules of the EPICURE statistical software package were 
used for the analyses [19]. 
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  RESULTS 
From 12 to 52 years after the first cancer, 13 patients had developed a KC, six of which 
were on the left side and seven on the right side. Ten were renal cell carcinoma, two were 
papillary renal cell carcinoma and one was a chromophobe renal cell carcinoma. Of these 
13 patients, 11 had returned the self-questionnaire, the other KC having been identified 
from clinical medical records. 
The cumulative incidence of KC was 0.05% (95CI: 0.01%-0.21%) 20 years after the 1st 
cancer diagnosis, 0.20% (95CI: 0.09%-0.45%) 30 years after, and 0.60% (95CI: 0.27%-1.38%) 
40 years after the diagnosis. This incidence was 13.4-fold higher (95%CI: 7.5-22.2) than 
expected in the general population (Table II), this ratio remained similar (SIR=15.2, 95%CI: 
7.6-26.7) when the analysis was restricted to patients who returned the questionnaire, 
remained stable during the time since the childhood cancer; whereas the Absolute Excess 
Risk (AER) strongly increased (p<0.0001) with increased duration of follow-up (Table II).  
Adjusting or not on other risk factors, KC risk increased with kidney radiation dose up to 
10-19.9 Gy, and decreased or plateaued for higher doses  (Table II). Figure 2 shows the 
cumulative incidence of KC by time since childhood cancer according to the kidney 
radiation dose. 
When modeling these variations, a model including a linear term plus a negative 
exponential term, fitted the data significantly more adequately (p=0.03) than a purely 
linear model. In this linear-exponential model, the linear dose coefficient was 1.1 (95%CI: 
0.1- 9.8) (Figure 3). 
Age at childhood cancer diagnosis did not significantly modify risk of KC nor radiation 
dose response (p=0.2). No significant difference in radiation sensitivity, as measured by 
the linear term, was observed according to gender (p>0.5), nor to the length of follow-up 
(p>0.5).  
Chemotherapy was significant risk factor (p=0.01) for KC (RR=5.1, 95%CI: 1.1-22.7), but 
we were not able to identify any chemotherapeutic drug or drug category specifically 
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associated with an increased risk of KC. Due to the small number of KC cases, it was not 
possible to study the role of chemotherapy as a dose-response modifier for radiation. We 
failed to evidence an increased risk associated to cisplatin (282 survivors, 1 KC) or to 
cyclophosphamide administration (1579 survivors, 6 KCs). 
Of the 13 KCs, four had occurred after nephroblastoma as a first cancer (RR=3.3, 95%CI: 
1.0-18.3), but this over risk disappeared when adjusting for chemotherapy, radiation dose 
to the kidney, year of treatment, sex and age at first cancer (table IIII).  
Of the 829 patients treated for a nephroblastoma, 18 had not undergone a nephrectomy 
of whom one had developed a second KC, 395 had undergone a right nephrectomy and 416 
a left nephrectomy, among whom, respectively, two, and one later developed a second KC 
on the remaining kidney.  
 
DISCUSSION 
 
Based on a cohort of 4,350 5-year survivors of childhood cancer followed up for an 
average of 27 years and 13 second KCs, this study showed that the main risk factor for a 
second KC is the radiation dose to kidneys, the risk increasing with increasing moderate 
doses but the trend seems to decrease at higher doses. As compared to that expected in 
the general population, the SIR of KC remained quite stable during the follow-up, but the 
annual excess incidence strongly increased with increasing follow-up. We identified a 
significant increase in the risk associated with chemotherapy, but we were unable to 
identify any specific drug associated with an increased risk. 
Despite the relatively large size of the cohort and the long duration of the follow-
up, the main limitation of our study is the small number of KCs, 13 cases, which strongly 
limits the analysis of risk factors. 
Overall, the incidence of KC was 13.5-fold (95%CI: 7.4 to 22.2) higher in our cohort 
than that expected from the general French and UK population incidence rates. This ratio 
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is higher to that observed in the CCSS, SIR=8.0 (95%CI: 5.2-11.4) [5], but close to the one 
observed in the BCCSS, SIR=10.6 (95%CI: 5.5 to 20.4) [1]. 
We observed an increase in the risk of KC with increasing kidney radiation doses, up 
to 10 to 19.9 Gy (RR = 13.8, 95% CI 3.1–60.9), and a decrease for higher doses. For low 
doses and moderate doses, up to a tenth of a Gray, each Gray to the kidney increased the 
risk of KC by a factor 1.1 (95%CI: 0.1 to 9.8). Overall, our result is in agreement with the 
relative risk of 3.8 (95%CI 1.6-9.3) for radiation to kidney of 5 Gy or higher evidenced in 
the CCSS [5]. 
The shape of the dose-response pattern we evidenced for KC following radiation 
exposure is consistent with the cell-killing hypothesis proposed by Louis Gray in 1964 [20] 
and resembles findings for Thyroid cancer [21]. By contrast, results of two studies of breast 
[212] and lung cancer [213] after Hodgkin's lymphoma showed that second-cancer risks for 
both sites were linear over a wide range of radiation doses. The highest doses to the breast 
and lung exceeded 40 Gy and 30 Gy, respectively—i.e., within the range that we observed 
the fall in risk of KC. However, small numbers of patients who received low doses might 
have diminished the ability to detect a risk reduction at doses more than 30 Gy [212-23]. 
We presumed that the presence of these conditions in many of the patients who received 
high doses of radiation indicated that cells in the thyroid and kidney tissues were killed or 
that the surviving cells had lost their capacity to proliferate. 
However, larges studies are needed to increase confidence in the shape of the 
dose-response curve. 
If confirmed in analyses including more patients, the clinical implications of our 
finding is that radiation doses of 2-5 Gy delivered to a large volume of healthy tissue 
during intensity-modulated radiation therapy (IMRT) would be as carcinogenic for kidneys 
as the ones of 40 Gy or higher received when included or very near the target radiation 
therapy volume. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10
The magnitude of the excess risk we found for low and moderate radiation doses 
appears to be that evidenced in Hiroshima-Nagasaki survivors, in whom an ERR/Sv = 2.82 
(90% CI: 0.45-8.89) [24]. This may probably be attributed to dose fractionation. 
In our cohort, chemotherapy was associated with an increase in KC, but we were 
unable to identify any specific drug or drug category responsible for this increase, and did 
not confirm neither the specific role of cisplatin exposure (RR = 3.5, 95%CI: 1.0- 11.2) 
observed in the CCSS [5], nor the one of cyclophosphamide evidenced in a study of NHL 
survivors [25]. In fact, until now, the total number of second KCs observed in the main 
childhood cancer cohorts, including the CCSS (n=26), is certainly too small to investigate 
the role of a specific type of drugs. 
Another important finding was the stability of the SIR compared to the incidence in 
the general population, during the follow-up since the childhood cancer (and therefore 
with attained age), even when adjusted on the kidney radiation dose. Due to the strong 
increase in KC with increasing age in the general population aged 50 years or more, the 
stability of the SIR in childhood cancer survivors will, as a consequence, shows a strong 
increase in the incidence of KC in childhood cancer survivors when they get older. This is 
what has been observed in the large scale Nordic Childhood Cancer Research Group cohort, 
in which KC was not specifically investigated, but in which urinary system cancer 
accounted for 2% of all second malignancies during the first 15 years of follow-up, but 60 
years later, the figure had attained 10% [26].  
Some authors suggested a genetic predisposition of neuroblastoma to the 
subsequent development of KC [27]. We were unable to confirm or to refute this result, 
but the small number of KCs in our study strongly limited our power to identify such a 
predisposition. 
The findings in this paper may not be generalizable for children diagnosed after 1986. 
Further analyses have to be conducted on the extended French cohort, which includes 5-
year survivors diagnosed from 1986 to 2000. That allows us to study a new radiotherapy 
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strategies such as IMRT and proton-therapy and also to study the risk related to the 
increasing in utility of the platinum-based agents as well as the introduction of the new 
chemotherapy agents.  
As treatment-related complications may occur many years after radiotherapy, our findings 
support lifetime medical surveillance and screening for potential KC. We believe that 
ultrasound, computed tomography  scanning and magnetic resonance imaging  are the best 
available tools to screening for potential KC. 
In conclusion, KC incidence will increase in the future in childhood cancer 
populations, because in our cohort, the ratio between expected and observed number of 
KC is constant during follow-up and the expected number will strongly increase when 
survivors will be older. The increase in risk of KC is similar after moderate kidney radiation 
dose (2-5 Gy) to the risk after high radiation doses. Chemotherapy increases KC risk, but 
we were not able to identify a specific drug responsive for this increase. Lastly urologists 
should inquire into the antecedents of their oncology patients and to stay informed that a 
history of chemotherapy or of radiation therapy is a risk factor for KC. 
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FIGURES LEGEND 
FIGURE 1: Average radiation dose to kidneys in Wilms tumor survivors and in survivors in 
survivors from other cancer types. 
FIGURE 2: Cumulative Kidney carcinoma incidence according to the kidney radiation dose, and 
expected incidence in the cohort, according to UK and French cancer registries. 
FIGURE 3: Kidney carcinoma risk by radiation dose to kidney.  
Linear dose-response model for relative risk calculated as: 1+020(dose).  
Linear-exponential dose-response model for relative risk calculated as 1+(11dose) e(–0067 
dose). Vertical lines=95% CIs for RR. 
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Table I : General characteristics of the 4,350  5-years survivors from a childhood cancer. 
 
Secondary kidney 
carcinoma (n=13) 
No secondary 
kidney carcinoma 
(n=4337) 
Years of treatment :  mean (range) 
1970 (1951-
1984) 
1974 (1942-1986) 
Country of treatment :  France / UK 12/1 3,121 / 1,216 
Age at diagnosis in years :  mean  (range)  6 (0-13) 6 (0-16) 
Sex : males / females  7 / 6 2,405 / 1,932 
1st cancer treatment n    
No Ct no Rt - 432 
Rt  no Ct 2 966 
Ct no Rt 2 927 
Rt & Ct 9 2012 
Mean follow-up in years (range) 27 (5-64) 27 (5-64) 
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Table II: Kidney carcinoma risk according to the radiation dose to the kidney in a cohort of 4,350 5-year childhood cancer survivors. 
 
 Patients Observed / 
Expected* 
Kidneys 
cancers   
Standardized 
Incidence Ratio 
(95%CI) 
Absolute Excess 
Risk (AER) per 
100.000 people per 
year (95%CI) 
Relative Risk 
(95%CI)** 
All cohort 4,350 13 / 0.97 13.5 (7.4-22.2) 7.9 (3.4-14.8) - 
Years after childhood 
cancer  
     
5-19 4,350 2 / 0.28 7.1 (1.2-21.9) 2.3 (0.2-7.6) - 
20-29 3,308 4 / 0.23 18.7 (5.8-43.3) 14.4 (3.8-34.7) - 
30-39 1,592 3 / 0.27 11.4 (2.8-29.6) 27.0 (4.8-74.3) - 
40+ 519 4 / 0.19 21.6 (6.7-50.1) 107.8 (24.1-269.4) - 
Attained age       
5-29 4,350 3 / 0.33 9.1 (2.3-23.5) 3.3 (0.7-8.9) - 
30-39 2,693 5 / 0.22 22.8 (8.2-49.0) 29.4 (9.6-64.8) - 
40-49 1,189 3 / 0.27 11.1 (2.8-28.8) 38.5 (3.6-113.0) - 
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50+ 324 2 / 0.15 13.7 (2.3-42.4) 76.7 (13.4-440.7) - 
Gender      
Male 2412 7 / 0.60 11.8 (5.0-22.7) 6.5 (1.4-16.6) 1 (ref) 
Female 1938 6 / 0.37 16.2 (6.4-32.8) 10.1 (3.1-22.3) 0.9 (0.3-3.0) 
Chemotherapy      
No 1,400 2 / 0.43 4.6 (0.8-14.3) 4.6 (0.8-14.3) 1 (ref) 
Yes 2,950 11 / 0.54 20.6 (10.7-35.2) 14.6 (0.8-25.0) 5.1 (1.1-22.7) 
Average  Kidney  radiation 
dose (in grays) 
     
No Rt or < 1 Gy 2,764 3 / 0.56 5.3 (1.3-13.8) 4.0 (1.0-10.5) 1 (ref) 
1   to 4.9 Gy 316 1 / 0.13 7.6 (0.4-33.5) 7.0 (0.4-30.9) 1.7 (0.2-17.4) 
5 to 9.9 Gy 203 2 / 0.09 22.2 (3.5-65.8) 19.9 (3.3-61.5) 5.3 (0.9-32.0) 
10 to 19.9 Gy  548 5 / 0.08 66.6 (23.2-138.8) 47.7 (17.1-102.5) 13.8 (3.1-60.9) 
20 Gy or more 519 2 / 0.07 27.3 (4.5-84.3) 22.5 (3.7-69.5) 4.7 (0.7-31.8) 
* Expected number of kidney carcinoma in the cohort, from the incidence in French and UK population 
** Relative risk in a Cox proportional hazard model with clustering in order to take into account the fact that each patient has 2 kidneys, 
adjusted on gender, date and age of diagnosis, and chemotherapy. 
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Table III : Kidney carcinoma according to the type of first cancer, in a cohort of 4,350 5-year childhood solid cancer survivors 
patients, of whom 2,989 had received external beam radiation therapy. 
First cancer type Cases / 
Patients 
Radiation 
therapy 
(%) 
Kidney radiation 
dose: mean, median 
(range) 
Absolute 
Excess of Risk 
per 100.000 
people per year 
(95%CI) 
Standardized 
Incidence Ratio 
(95%CI)* 
Relative Risk 
(95%CI)** 
Nephroblastoma 4/829 73 13.9, 14.6 (0.3-57.7) 13.9 (2.5-36.6) 22.3 (6.3-51.7) 1.5 (0.3-8.4) 
Neuroblastoma 2/580 55 5.5, 0.1 (0-48.4) 12.9 (0.0-40.1) 19.4 (3.2 -59.9) 1.5 (0.1-18.0) 
Gonadal tumor 1/233 39 5.3, 0.0 (0.1 - 44.8) 15.2 (0.0-72.0) 17.4 (1.0-76.6) 1.5 (0.2-11.1) 
Other 1st cancers 6/2708 72 3.5, 0.1 (0 - 57.1) 5.1 (0.6-3.0) 9.9 (3.4-20.1) 1 (ref)* 
* As compared to the incidence in French and UK general population 
** Relative risk in a Cox proportional hazard model with clustering in order to take into account the fact that each patient has 2 kidneys, 
adjusted on gender, date and age of diagnosis, and chemotherapy. 
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Figure 1 
 
 
 
0
100
200
300
400
500
600
700
800
Radiation dose to kidney (Gy)
0 0.1 0.5 0.5 1 2 3 5 10 15 20 30
0
100
200
300
Radiation dose to kidney (Gy)
0 0.1 0.5 0.5 1 2 3 5 10 15 20 30
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
 
Figure 2 
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Figure 3 
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KC: Kidney Carcinoma 
CI: Confidence Interval 
SIR: Standardized Incidence Ratio  
CCSS: Childhood Cancer Survivor Study 
Cst: Constant 
Gy: Gray 
